文献速递睡眠呼吸障碍

GLP-1受体激动剂预防2型糖尿病患者阻塞性睡眠呼吸暂停的有效性:活性对照、新用药者队列研究

Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study.
PubMed 文献 · Am J Respir Crit Care Med · 2026-09-15

基于英国CPRD数据库(2007-2023)的活性对照、新用药者人群队列研究,纳入BMI≥30 kg/m²、无睡眠呼吸暂停史的2型糖尿病成人,比较GLP-1受体激动剂与DPP-4抑制剂起始者的新发阻塞性睡眠呼吸暂停风险。GLP-1RA组与DPP-4i组新发OSA风险无显著差异(HR 1.07,95%CI 0.93-1.23)。

要点

  • 在BMI≥30 kg/m²的2型糖尿病患者中,GLP-1RA相比DPP-4i未降低新发OSA风险。
  • GLP-1RA组与DPP-4i组OSA发病率分别为5.8与5.4/1000人年。
  • 结果在BMI分层、性别、药物类型及多项敏感性分析中一致。

核心结论

  • 在常规临床实践中,与DPP-4i相比,GLP-1RA未降低无OSA病史的2型糖尿病患者的OSA发病率。

研究设计与样本

  • 基于英国CPRD数据库(2007-2023)的活性对照、新用药者人群队列研究。
  • 纳入BMI≥30 kg/m²且起始GLP-1RA或DPP-4i的2型糖尿病成人,排除既往睡眠呼吸暂停者。
  • 采用倾向评分精细分层加权,按BMI分层分析,随访最长3年,采用as-treated分析。

主要发现

  • 队列包括47,315例GLP-1RA起始者和159,066例DPP-4i起始者,加权后基线特征均衡良好。
  • 随访期间GLP-1RA组与DPP-4i组分别发生612例和1,197例新发OSA,发病率分别为5.8与5.4/1000人年。
  • GLP-1RA相比DPP-4i的新发OSA风险比HR为1.07(95%CI 0.93-1.23)。
  • 结果在BMI分层、性别、药物类型及多项敏感性分析中一致。

临床怎么用

  • 提示不应以预防OSA为主要目的在2型糖尿病合并肥胖患者中选用GLP-1RA,其OSA预防获益未获本队列支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Obstructive sleep apnea (OSA) is highly prevalent in type 2 diabetes (T2D), sharing metabolic risk factors, notably obesity, and increased cardiovascular outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to reduce OSA severity in clinical trials but their role in preventing incident OSA in T2D remains unclear. OBJECTIVE: To assess whether GLP-1RA use is associated with a reduced risk of incident OSA compared with dipeptidyl peptidase-4 inhibitors (DPP-4i), a weight-neutral comparator, in patients with T2D. METHODS: We conducted a population-based cohort study using the UK CPRD (2007-2023) database with an active-comparator, new-user design. Adults with T2D and BMI ≥30 kg/m² initiating a GLP-1RA or DPP-4i were included, excluding individuals with prior sleep apnea. Propensity scores with fine-stratification weighting were used within BMI strata. The primary outcome was incident clinical diagnosis of OSA. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs) using an as-treated approach, with up to 3 years of follow-up. RESULTS: The cohort included 47,315 GLP-1RAs and 159,066 DPP-4i initiators with baseline characteristics well balanced after weighting. During follow-up, 612 and 1,197 incident OSA cases occurred among GLP-1RAs and DPP-4i users, yielding incidence rates of 5.8 and 5.4 per 1000 person-years, respectively. The HR of incident OSA with GLP-1RA use compared with DPP-4i use was 1.07 (95% CI 0.93-1.23). Results were consistent across BMI strata, sex, drug type, and multiple sensitivity analyses. CONCLUSIONS: In routine clinical care, GLP-1RAs were not associated with a decreased incidence of OSA in patients with T2D and no history of OSA, when compared with DPP-4i.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Khouri C, Dell'Aniello S, Jambon Barbara C, et al. Effectiveness of GLP-1 receptor agonists to prevent obstructive sleep apnea in patients with type 2 diabetes: active comparator, new user cohort study. Am J Respir Crit Care Med. 2026. PMID: 42745463. doi:10.1093/ajrccm/aamag474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。